- AIKI chart is set to go on a nice run.
- Recently, the company in March did a raise at $1.60.
- Warrant coverage at $3.08 sets up a nice mid move to $1.50.
- Possible "Covid promotion" news coming.
AIkido Pharma (AIKI) chart is indicating a possible so-called "Pump" is coming. Recently in March, the company closed an offering at $1.60 There are substantial warrant coverage at $3.08 which equates to what we believe will be a promotion campaign here for the warrant holders to finish their short cover and turn long.
Additionally, the CEO has been open-buying stock at around $1 as well as a new board member with extensive virology experience.
Also, company cancelled a recent S1 shelf filing, we believe because they have something else 'brewing.'
It's also possible this one could see a reverse merger deal as the shell here is cash rich, with cash value at $1.15 a share, over $100M of cash in hand. One of our recent reverse merger play is Aeripo (ARPO), which has been an excellent trade for us and our followers
Notwithstanding the bullish chart, we believe there are multiple factors that could see this stock double over the next 3 weeks. Let's take a look at the chart;
The apex high here in March was $2.55 a share, This is to the left - red candle before gap down from announcing their raise in March. We see this level as the top end here.
The 2nd white line is, the gap down below that is $1.26 - our first target sell price here. with $1.15 being first resistance level.
The 3rd white line is $1.21, which we see as the pivot above $1.15 resistance.
RSI is headed in the right direction, with MACD just beginning to cross the 0 zine to positive. The purple line is the accumulation/distribution indicator, which is pointing slightly up.
The next one is the blue line money flow indicator, that suggests to us that short covering is underway here as the line is pointing down,with an increasing price from 2 valleys, currently increasing from the elongated valley area.
Price target sell opinions:
The above price targets are within "the reasonable range of expectation."
Head end is around $2.55 a share.
Possible news outlier;
Since company cancelled their shelf, it's possible since it has a somewhat legit Covid asset, that someone might be providing more financing for them. Now, this is a possibility, we don't know if it's likely or not. Our main focus is the bullish chart here and potential of (XBI) to see a nice run up into ASCO, provided bond yields stay stable.
To hear our audio and participate in our daily chat, go to Join the StockMatusow Stock Audio & Chat Discord Server! (Click on broadcast under the "voice channel"on the left to hear audio.)
It's free, and we constantly give commentary on biotech, and just about everything else in the market, from short term trades to long term holds, and everywhere in between.
Our best buy and hold play/investments in dev.Biotech are Calithera (OTC:CALA) (we own it) and Glycomimetics (GLYC) (which we currently do not own) Come into our room and we will make our case as to why. We also welcome all opinions, but please make your case, just don't simply "bash" or "pump." thanks!
Analyst's Disclosure: I am/we are long ARPO, CALA, AIKI.
Disclaimer: this article is intended for informational and entertainment use only, and should not be construed as professional investment advice. They are our opinions only. Trading stocks is risky - always be sure to know and understand your risk tolerance. You can incur substantial financial losses in any trade or investment. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.